RAD Technology Medical Systems to Provide VRCC Veterinary Specialty and Emergency Hospital with Standalone Radiotherapy Center

RAD Technology Medical Systems (RAD) is pleased to announce that they will be providing Veterinary Referral Center of Colorado, also know as, VRCC Veterinary Specialty and Emergency Hospital (VRCC) in Sheridan, CO with a veterinary radiotherapy center. This facility will allow VRCC to provide improved radiation therapy treatment to animals with cancer.

RAD’s patented technology and offsite modular construction methods provide their customers with a flexible, high-quality facility solution that is completed ahead of conventional construction.

RAD’s modular radiotherapy center was the perfect solution for the growing VRCC. They were looking for a quick solution that would allow them to upgrade their services in the region. They selected a pre-existing RAD facility that will be updated and expanded to meet all of their specific program needs.

Unlike with conventionally built radiotherapy centers, RAD’s facility and equipment will be able to make Beam within 5-7 days of its arrival on site, and will be ready to treat patients within 30 days of arrival.

This facility originally served as a Temporary Radiotherapy Vault, or RAD Temp, and was previously used by cancer centers from coast to coast, in five states and the District of Columbia, to treat patients while those cancer centers upgraded their radiotherapy equipment.

“We are excited to be entering the Veterinary Market,” said Kenneth Wright, RAD’s Vice President of Sales and Business Development. “The veterinary oncology market is growing and our modular approach is the perfect solution for veterinary offices looking to expand or add radiation treatment to their location.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy